NCT01609062
MPS IVA, Morquio A Syndrome, Mucopolysaccharidosis IVA
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the pharmacokinetic (PK) parameters of both doses of BMN 110 was assessed.
All
From 7 Years
No
BMN 110, BMN 110
Phase 2
Interventional
25
2012-04
2016-02-01
Oakland, California, United States
Chicago, Illinois, United States
New York, New York, United States
Houston, Texas, United States
Calgary, Alberta, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Sherbrook, Quebec, Canada
Hamburg, , Germany
Belfast, Northern Ireland, United Kingdom
Manchester, , United Kingdom
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields